Patrome regulatory update

Impax submitted an MAA to EMA for IPX066 to treat idiopathic Parkinson's disease. The extended-release capsule formulation of carbidopa-levodopa is under review in the U.S. under the brand name Rytary for symptomatic treatment of PD with a Jan. 9, 2015 PDUFA date (see BioCentury, Sept. 22). ...